|
CZ20004727A3
(cs)
*
|
1998-06-19 |
2002-03-13 |
Pfizer Products Inc. |
Deriváty pyrrolo[2,3-d] pyrimidinu
|
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
AU777911B2
(en)
|
1999-12-10 |
2004-11-04 |
Pfizer Products Inc. |
Pyrrolo(2,3-d)pyrimidine compounds
|
|
UA74370C2
(uk)
*
|
2000-06-26 |
2005-12-15 |
Пфайзер Продактс Інк. |
Піроло(2,3-d)піримідинові сполуки як імуносупресори
|
|
WO2002024667A1
(en)
|
2000-09-20 |
2002-03-28 |
Merck Patent Gmbh |
4-amino-quinazolines
|
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
|
DE10063294A1
(de)
*
|
2000-12-19 |
2002-07-04 |
Aventis Pharma Gmbh |
Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
|
|
WO2002060492A1
(en)
*
|
2001-01-30 |
2002-08-08 |
Cytopia Pty Ltd |
Methods of inhibiting kinases
|
|
AU2002256615B2
(en)
|
2001-02-12 |
2007-09-13 |
F. Hoffmann-La Roche Ag |
6-substituted pyrido-pyrimidines
|
|
US7301023B2
(en)
*
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
|
GB0115393D0
(en)
*
|
2001-06-23 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
CA2452361A1
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating autoimmune diseases
|
|
US7727731B2
(en)
|
2001-06-29 |
2010-06-01 |
Ab Science |
Potent, selective and non toxic c-kit inhibitors
|
|
ES2274075T3
(es)
*
|
2001-06-29 |
2007-05-16 |
Ab Science |
Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
|
|
US7700610B2
(en)
|
2001-06-29 |
2010-04-20 |
Ab Science |
Use of tyrosine kinase inhibitors for treating allergic diseases
|
|
ES2266553T3
(es)
|
2001-06-29 |
2007-03-01 |
Ab Science |
Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
|
|
US7323469B2
(en)
|
2001-08-07 |
2008-01-29 |
Novartis Ag |
7H-pyrrolo[2,3-d]pyrimidine derivatives
|
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
|
US7829566B2
(en)
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
|
GT200200234A
(es)
|
2001-12-06 |
2003-06-27 |
|
Compuestos cristalinos novedosos
|
|
ES2305435T3
(es)
|
2002-01-10 |
2008-11-01 |
Bayer Healthcare Ag |
Inhibidores de la rho-quinasa.
|
|
CA2473510A1
(en)
|
2002-01-23 |
2003-07-31 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
|
DE60318177T2
(de)
|
2002-01-23 |
2008-10-09 |
Bayer Pharmaceuticals Corp., West Haven |
Rho-kinase inhibitoren
|
|
GB0202679D0
(en)
*
|
2002-02-05 |
2002-03-20 |
Glaxo Group Ltd |
Novel compounds
|
|
EP1388541A1
(en)
*
|
2002-08-09 |
2004-02-11 |
Centre National De La Recherche Scientifique (Cnrs) |
Pyrrolopyrazines as kinase inhibitors
|
|
BR0316487A
(pt)
*
|
2002-11-26 |
2005-10-11 |
Pfizer Prod Inc |
Método todo de tratamento da rejeição de transplantes
|
|
EP1682564A1
(en)
*
|
2003-10-27 |
2006-07-26 |
Genelabs Technologies, Inc. |
METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES
|
|
BRPI0416909A
(pt)
*
|
2003-11-25 |
2007-01-16 |
Pfizer Prod Inc |
método de tratamento de aterosclerose
|
|
US20090036448A1
(en)
*
|
2004-03-30 |
2009-02-05 |
Taisho Pharmecutical Co., Ltd. |
Pyrimidine derivatives and methods of treatment related to the use thereof
|
|
EP1768662A2
(en)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Small molecule immunopotentiators and assays for their detection
|
|
CA2572314A1
(en)
*
|
2004-06-29 |
2006-01-12 |
Christopher N. Farthing |
Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity
|
|
WO2006017443A2
(en)
|
2004-08-02 |
2006-02-16 |
Osi Pharmaceuticals, Inc. |
Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
|
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
WO2006091450A1
(en)
*
|
2005-02-18 |
2006-08-31 |
Lexicon Genetics Incorporated |
4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
|
|
KR20080025039A
(ko)
|
2005-05-13 |
2008-03-19 |
아이알엠 엘엘씨 |
단백질 키나제 억제제로서의 화합물 및 조성물
|
|
CN102127078A
(zh)
|
2005-07-14 |
2011-07-20 |
安斯泰来制药株式会社 |
Janus激酶3的杂环类抑制剂
|
|
CA2615291A1
(en)
|
2005-07-14 |
2007-01-18 |
Astellas Pharma Inc. |
Heterocyclic janus kinase 3 inhibitors
|
|
EP2270014A1
(en)
|
2005-09-22 |
2011-01-05 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
|
ES2401192T3
(es)
*
|
2005-09-30 |
2013-04-17 |
Vertex Pharmceuticals Incorporated |
Deazapurinas útiles como inhibidores de janus cinasas
|
|
DK3184526T3
(en)
|
2005-12-13 |
2019-01-14 |
Incyte Holdings Corp |
PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
|
|
EP2007373A4
(en)
*
|
2006-03-29 |
2012-12-19 |
Foldrx Pharmaceuticals Inc |
INHIBITION OF ALPHA SYNUCLEINE TOXICITY
|
|
FI3719018T3
(fi)
|
2006-04-25 |
2025-10-07 |
Astex Therapeutics Ltd |
Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä
|
|
US8513270B2
(en)
|
2006-12-22 |
2013-08-20 |
Incyte Corporation |
Substituted heterocycles as Janus kinase inhibitors
|
|
EP2123651A4
(en)
|
2007-01-12 |
2011-05-04 |
Astellas Pharma Inc |
CONDENSED PYRIDINE COMPOUND
|
|
AU2008234822A1
(en)
*
|
2007-04-02 |
2008-10-09 |
Palau Pharma, S. A. |
Pyrrolopyrimidine derivatives as JAK3 inhibitors
|
|
EP2740731B1
(en)
|
2007-06-13 |
2016-03-23 |
Incyte Holdings Corporation |
Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
DE102007027800A1
(de)
|
2007-06-16 |
2008-12-18 |
Bayer Healthcare Ag |
Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
|
|
CA2705319C
(en)
*
|
2007-11-10 |
2019-01-15 |
Laurence Reid |
Systems and methods for workflow automation, adaptation and integration
|
|
ES2610190T3
(es)
*
|
2007-11-28 |
2017-04-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibidores de miristato de moléculas pequeñas de Bcr-abl y métodos de uso
|
|
MX2010008719A
(es)
|
2008-02-06 |
2010-09-24 |
Novartis Ag |
Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina.
|
|
RU2503676C2
(ru)
*
|
2008-02-25 |
2014-01-10 |
Ф.Хоффманн-Ля Рош Аг |
Пирролопиразиновые ингибиторы киназы
|
|
ES2602577T3
(es)
|
2008-03-11 |
2017-02-21 |
Incyte Holdings Corporation |
Derivados de azetidina y ciclobutano como inhibidores de JAK
|
|
WO2009115084A2
(de)
*
|
2008-03-20 |
2009-09-24 |
Schebo Biotech Ag |
Neue pyrrolopyrimidin-derivate und deren verwendungen
|
|
JP2011526931A
(ja)
*
|
2008-07-03 |
2011-10-20 |
エグゼリクシス， インコーポレイテッド |
Ｃｄｋモジュレーター
|
|
BRPI0916931A2
(pt)
*
|
2008-08-01 |
2015-11-24 |
Biocryst Pharm Inc |
agentes terapêuticos
|
|
RU2493157C2
(ru)
*
|
2008-08-20 |
2013-09-20 |
Пфайзер Инк. |
ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА
|
|
US8385364B2
(en)
*
|
2008-09-24 |
2013-02-26 |
Nec Laboratories America, Inc. |
Distributed message-passing based resource allocation in wireless systems
|
|
CA3025627C
(en)
|
2009-04-20 |
2021-08-31 |
Auspex Pharmaceuticals, Inc. |
Piperidine inhibitors of janus kinase 3
|
|
WO2010135621A1
(en)
|
2009-05-22 |
2010-11-25 |
Incyte Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
|
ES2487542T3
(es)
|
2009-05-22 |
2014-08-21 |
Incyte Corporation |
Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus
|
|
TW201105674A
(en)
|
2009-07-08 |
2011-02-16 |
Leo Pharma As |
Novel JAK receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof
|
|
TWI466885B
(zh)
|
2009-07-31 |
2015-01-01 |
Japan Tobacco Inc |
含氮螺環化合物及其醫藥用途
|
|
TW201111385A
(en)
*
|
2009-08-27 |
2011-04-01 |
Biocryst Pharm Inc |
Heterocyclic compounds as janus kinase inhibitors
|
|
WO2011028685A1
(en)
|
2009-09-01 |
2011-03-10 |
Incyte Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
CA2777114C
(en)
|
2009-10-09 |
2018-10-23 |
Incyte Corporation |
Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
|
WO2011045702A1
(en)
|
2009-10-15 |
2011-04-21 |
Pfizer Inc. |
Pyrrolo[2,3-d] pyrimidine compounds
|
|
CA2782720A1
(en)
|
2009-12-18 |
2011-06-23 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
CN102822177A
(zh)
|
2010-02-05 |
2012-12-12 |
美国辉瑞有限公司 |
吡咯并[2,3-d]嘧啶脲化合物
|
|
EP2360158A1
(en)
*
|
2010-02-18 |
2011-08-24 |
Almirall, S.A. |
Pyrazole derivatives as jak inhibitors
|
|
SMT201800137T1
(it)
|
2010-03-10 |
2018-07-17 |
Incyte Holdings Corp |
Derivati di piperidin-4-il azetidina come inibitori di jak1
|
|
JP2013533868A
(ja)
*
|
2010-07-09 |
2013-08-29 |
レオ ファーマ アクティーゼルスカブ |
タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
|
|
ES2536415T3
(es)
|
2010-11-19 |
2015-05-25 |
Incyte Corporation |
Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
|
|
SG190839A1
(en)
|
2010-11-19 |
2013-07-31 |
Incyte Corp |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
BR112013017184A2
(pt)
|
2011-01-07 |
2016-09-20 |
Leo Pharma As |
composto, composição farmacêutica, uso de um composto, e, método para evitar, tratar ou melhorar doenças
|
|
ES2547916T3
(es)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
Terapia de combinación de inhibidores de mTOR/JAK
|
|
EP2688890B1
(en)
|
2011-03-22 |
2017-08-30 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
|
AU2012255792A1
(en)
*
|
2011-05-17 |
2013-11-07 |
Principia Biopharma Inc. |
Azaindole derivatives as tyrosine kinase inhibitors
|
|
WO2012177606A1
(en)
|
2011-06-20 |
2012-12-27 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
|
JP2014521725A
(ja)
|
2011-08-10 |
2014-08-28 |
ノバルティス・ファルマ・アクチェンゲゼルシャフト |
ＪＡＫＰＩ３Ｋ／ｍＴＯＲ併用療法
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
EP4556010A3
(en)
|
2011-11-30 |
2025-07-23 |
Emory University |
Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
|
|
WO2013091539A1
(zh)
*
|
2011-12-21 |
2013-06-27 |
江苏恒瑞医药股份有限公司 |
吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用
|
|
WO2013173720A1
(en)
|
2012-05-18 |
2013-11-21 |
Incyte Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
JP6235001B2
(ja)
|
2012-05-21 |
2017-11-22 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
置換ベンゾチエノピリミジン
|
|
MD20140130A2
(ro)
*
|
2012-06-29 |
2015-04-30 |
Pfizer Inc. |
4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
|
|
MY173845A
(en)
*
|
2012-07-17 |
2020-02-24 |
Glaxosmithkline Ip No 2 Ltd |
Indolecarbonitriles as selective androgen receptor modulators
|
|
PT2874630T
(pt)
|
2012-07-20 |
2019-01-31 |
Zoetis Services Llc |
Regime de dosagem para inibidores de janus quinase (jak)
|
|
TW201412740A
(zh)
|
2012-09-20 |
2014-04-01 |
Bayer Pharma AG |
經取代之吡咯并嘧啶胺基苯并噻唑酮
|
|
US9593115B2
(en)
|
2012-09-21 |
2017-03-14 |
Advinus Therapeutics Ltd. |
Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
|
|
CN102936251A
(zh)
*
|
2012-11-05 |
2013-02-20 |
上海毕得医药科技有限公司 |
一种吡咯并[2,3-d]嘧啶衍生物的制备方法
|
|
PE20151157A1
(es)
|
2012-11-15 |
2015-08-19 |
Incyte Corp |
Formas de dosificacion de ruxolitinib de liberacion sostenida
|
|
KR101683061B1
(ko)
*
|
2013-02-07 |
2016-12-07 |
한국과학기술연구원 |
ＪＡＫ-3 저해제로 유용한 ７Ｈ-피롤로[2,3-ｄ]피리미딘-4-싸이올 유도체
|
|
EP2958921B1
(en)
|
2013-02-22 |
2017-09-20 |
Pfizer Inc |
Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus kinases (jak)
|
|
LT3489239T
(lt)
|
2013-03-06 |
2022-03-10 |
Incyte Holdings Corporation |
Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai
|
|
EP2970119B1
(en)
*
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
UA120499C2
(uk)
|
2013-08-07 |
2019-12-26 |
Інсайт Корпорейшн |
Лікування захворювань із застосуванням лікарських форм з уповільненим вивільненням для інгібітора jak1
|
|
MA39092B1
(fr)
|
2013-12-05 |
2018-09-28 |
Pfizer |
Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
|
|
WO2015092592A1
(en)
|
2013-12-17 |
2015-06-25 |
Pfizer Inc. |
Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
EP3180344B1
(en)
|
2014-08-12 |
2019-09-18 |
Pfizer Inc |
Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
|
|
EP3288943B1
(en)
|
2015-05-01 |
2022-09-28 |
Pfizer Inc. |
Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase
|
|
MX381994B
(es)
*
|
2015-05-29 |
2025-03-13 |
Wuxi Fortune Pharmaceutical Co Ltd |
Inhibidor de janus quinasa.
|
|
KR101771219B1
(ko)
*
|
2015-08-21 |
2017-09-05 |
양지화학 주식회사 |
야누스 키나제 1 선택적 억제제 및 그 의약 용도
|
|
RU2722149C1
(ru)
|
2015-09-14 |
2020-05-27 |
Пфайзер Инк. |
Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
|
|
CN106831779B
(zh)
*
|
2015-11-28 |
2019-07-19 |
南昌弘益药业有限公司 |
一类jak激酶抑制剂的新化合物
|
|
EP3416965B1
(en)
|
2016-02-16 |
2020-10-07 |
Zoetis Services LLC |
Process for preparing 7h-pyrrolo [2,3-d]pyrimidine compounds
|
|
CN107098908B
(zh)
*
|
2016-02-23 |
2021-01-08 |
欣凯医药科技(上海)有限公司 |
一种吡咯并嘧啶类化合物的制备方法和应用
|
|
CN117756789A
(zh)
|
2016-12-14 |
2024-03-26 |
英特维特国际股份有限公司 |
作为选择性Janus激酶抑制剂的氨基吡唑类化合物
|
|
JP6944496B2
(ja)
|
2018-10-22 |
2021-10-06 |
ファイザー・インク |
ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
|
|
MX2021005334A
(es)
*
|
2018-11-05 |
2021-06-23 |
Avista Pharma Solutions Inc |
Compuestos quimicos.
|
|
US11174263B2
(en)
|
2018-12-31 |
2021-11-16 |
Biomea Fusion, Inc. |
Inhibitors of menin-MLL interaction
|
|
AU2019417833B2
(en)
|
2018-12-31 |
2024-11-07 |
Biomea Fusion, Inc. |
Irreversible inhibitors of menin-MLL interaction
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
EP3946606B1
(en)
|
2019-03-27 |
2025-01-01 |
Insilico Medicine IP Limited |
Bicyclic jak inhibitors and uses thereof
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
JP2023554665A
(ja)
|
2020-12-18 |
2023-12-28 |
ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド |
ホウ素含有ピラゾール化合物、それらを含む組成物、それらの方法及び使用
|
|
CA3228627A1
(en)
|
2021-08-11 |
2023-02-16 |
Thomas Butler |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
|
EP4387972A1
(en)
|
2021-08-20 |
2024-06-26 |
Biomea Fusion, Inc. |
Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
|
|
WO2023029943A1
(zh)
*
|
2021-09-03 |
2023-03-09 |
星药科技(北京)有限公司 |
一种芳杂环化合物及其制备方法和用途
|
|
WO2023055731A1
(en)
*
|
2021-09-28 |
2023-04-06 |
Sanford Burnham Prebys Medical Discovery Institute |
Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
|
|
MX2024007863A
(es)
|
2021-12-24 |
2024-08-30 |
Intervet Int Bv |
Uso de compuestos de aminopirazol.
|
|
GB202215117D0
(en)
*
|
2022-10-13 |
2022-11-30 |
Norwegian Univ Sci & Tech Ntnu |
Compound
|
|
GB202215132D0
(en)
*
|
2022-10-13 |
2022-11-30 |
Norwegian Univ Sci & Tech Ntnu |
Compound
|
|
WO2024155710A1
(en)
|
2023-01-18 |
2024-07-25 |
Biomea Fusion, Inc. |
Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
|